ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Zerhouni forms steering committee; Olden to retire.

August 1, 2003

In Brief: Conferees Ok NCI Appropriations At $691.7 Million; Final Amount Available Won’t Be Set Until Spring

November 29, 1974

ASCO Updates Guideline On Antiemetics

June 30, 2006

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

Henschke and Supporters Call For Urgent Action Based On Results Of NLST

May 13, 2011

Medicare plans to cut oncology payments on Jan. 1 unless Congress intervenes.

October 17, 2003